Released Mar 8, 2016, after the close
10-K filed Mar 8, 2016, 68 days after period end · 0001144204-16-086642
Q4 2015 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$0.00$0.00 derivedno prior Q4 2014 on file−100.0% vs Q3 2015
Net Income$72.90M$72.90M derivedN/M vs Q4 2014N/M vs Q3 2015
EPS, diluted—Not derived. Share counts vary by quarter.
Gross Profitderived$0N/M
Operating Incomederived-$7,700,000N/M
Operating Cash Flowderived-$3,857,000N/M
Free Cash Flowderived-$3,861,000N/M
What the release said
No earnings release is on file for this quarter. Its figures came with the 10-K.
Same quarter
| Metric | Q4 2015dderived from reported figures | Q4 2014dderived from reported figures | Q4 2013dderived from reported figures | Q4 2012dderived from reported figures |
|---|---|---|---|---|
| Revenue | $0.00 | — | — | $1.17M |
| Net Income | $72.90M | -$8.47M | -$10.89M | -$9.88M |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Protalix BioTherapeutics, Inc. · CIK 1006281 · Engraved from SEC EDGAR